{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T14:12:01Z","timestamp":1782396721310,"version":"3.54.5"},"reference-count":65,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2014,10,1]],"date-time":"2014-10-01T00:00:00Z","timestamp":1412121600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,10,1]],"date-time":"2014-10-01T00:00:00Z","timestamp":1412121600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2014,10,1]],"date-time":"2014-10-01T00:00:00Z","timestamp":1412121600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2014,10,1]],"date-time":"2014-10-01T00:00:00Z","timestamp":1412121600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2014,10,1]],"date-time":"2014-10-01T00:00:00Z","timestamp":1412121600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2014,10,1]],"date-time":"2014-10-01T00:00:00Z","timestamp":1412121600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2014,10,1]],"date-time":"2014-10-01T00:00:00Z","timestamp":1412121600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","trasci.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transfusion and Apheresis Science"],"published-print":{"date-parts":[[2014,10]]},"DOI":"10.1016\/j.transci.2014.10.003","type":"journal-article","created":{"date-parts":[[2014,10,15]],"date-time":"2014-10-15T22:21:29Z","timestamp":1413411689000},"page":"120-125","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":50,"title":["Ebola virus convalescent blood products: Where we are now and where we may need to go"],"prefix":"10.1016","volume":"51","author":[{"given":"Thierry","family":"Burnouf","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerard","family":"Seghatchian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.transci.2014.10.003_bib0010","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.tracli.2009.04.004","article-title":"Protecting the blood supply from emerging pathogens: the role of pathogen inactivation","volume":"16","author":"Blajchman","year":"2009","journal-title":"Transfus Clin Biol"},{"key":"10.1016\/j.transci.2014.10.003_bib0015","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1111\/bjh.12031","article-title":"Emerging pathogens and their implications for the blood supply and transfusion transmitted infections","volume":"159","author":"Dodd","year":"2012","journal-title":"Br J Haematol"},{"key":"10.1016\/j.transci.2014.10.003_bib0020","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1016\/S0140-6736(13)61492-0","article-title":"Interhuman transmissibility of Middle East respiratory syndrome coronavirus: estimation of pandemic risk","volume":"382","author":"Breban","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.transci.2014.10.003_bib0025","first-page":"199","article-title":"Treatment of severe acute respiratory syndrome with convalescent plasma","volume":"9","author":"Wong","year":"2003","journal-title":"Hong Kong Med J"},{"key":"10.1016\/j.transci.2014.10.003_bib0030","first-page":"489","article-title":"Successful treatment of avian influenza with convalescent plasma","volume":"12","author":"Kong","year":"2006","journal-title":"Hong Kong Med J"},{"key":"10.1016\/j.transci.2014.10.003_bib0035","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1111\/j.1537-2995.2010.02590.x","article-title":"Convalescent transfusion for pandemic influenza: preparing blood banks for a new plasma product?","volume":"50","author":"Leider","year":"2010","journal-title":"Transfusion"},{"key":"10.1016\/j.transci.2014.10.003_bib0040","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1002\/rmv.480","article-title":"Convalescent whole blood, plasma and serum in the prophylaxis of measles: JAMA, 12 April, 1926; 1180\u20131187","volume":"15","author":"Zingher","year":"2005","journal-title":"Rev Med Virol"},{"key":"10.1016\/j.transci.2014.10.003_bib0045","doi-asserted-by":"crossref","first-page":"599","DOI":"10.7326\/0003-4819-145-8-200610170-00139","article-title":"Meta-analysis: convalescent blood products for Spanish influenza pneumonia: a future H5N1 treatment?","volume":"145","author":"Luke","year":"2006","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.transci.2014.10.003_bib0050","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1136\/bmj.1.3708.183","article-title":"Convalescent serum in prophylaxis of measles, chicken-pox, and mumps","volume":"1","author":"Gunn","year":"1932","journal-title":"Br Med J"},{"key":"10.1016\/j.transci.2014.10.003_bib0055","series-title":"Position Paper on collection and use of convalescent plasma or serum as an element in filovirus outbreak response. WHO Blood Regulators Network (BRN). 14 August 2014","author":"Anonymous","year":"2014"},{"key":"10.1016\/j.transci.2014.10.003_bib0060","series-title":"Consultation on potential Ebola therapies and vaccines- Background document for participants","author":"WHO","year":"2014"},{"key":"10.1016\/j.transci.2014.10.003_bib0065","doi-asserted-by":"crossref","first-page":"g5539","DOI":"10.1136\/bmj.g5539","article-title":"First Ebola treatment is approved by WHO","volume":"349","author":"Gulland","year":"2014","journal-title":"Br Med J"},{"issue":"Suppl. 1","key":"10.1016\/j.transci.2014.10.003_bib0070","doi-asserted-by":"crossref","first-page":"S18","DOI":"10.1086\/514298","article-title":"Treatment of Ebola hemorrhagic fever with blood transfusions from convalescent patients. International Scientific and Technical Committee","volume":"179","author":"Mupapa","year":"1999","journal-title":"J Infect Dis"},{"key":"10.1016\/j.transci.2014.10.003_bib0075","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1136\/bmj.2.6086.541","article-title":"A case of Ebola virus infection","volume":"2","author":"Emond","year":"1977","journal-title":"Br Med J"},{"key":"10.1016\/j.transci.2014.10.003_bib0080","doi-asserted-by":"crossref","first-page":"6408","DOI":"10.1128\/JVI.76.12.6408-6412.2002","article-title":"Pre- and postexposure prophylaxis of Ebola virus infection in an animal model by passive transfer of a neutralizing human antibody","volume":"76","author":"Parren","year":"2002","journal-title":"J Virol"},{"key":"10.1016\/j.transci.2014.10.003_bib0085","doi-asserted-by":"crossref","first-page":"e1175","DOI":"10.1371\/journal.pntd.0001175","article-title":"Serologic cross-reactivity of human IgM and IgG antibodies to five species of Ebola virus","volume":"5","author":"Macneil","year":"2011","journal-title":"PLoS Negl Trop Dis"},{"issue":"Suppl. 2","key":"10.1016\/j.transci.2014.10.003_bib0090","doi-asserted-by":"crossref","first-page":"S347","DOI":"10.1086\/520581","article-title":"Epitopes required for antibody-dependent enhancement of Ebola virus infection","volume":"196","author":"Takada","year":"2007","journal-title":"J Infect Dis"},{"key":"10.1016\/j.transci.2014.10.003_bib0095","doi-asserted-by":"crossref","first-page":"7539","DOI":"10.1128\/JVI.77.13.7539-7544.2003","article-title":"Antibody-dependent enhancement of Ebola virus infection","volume":"77","author":"Takada","year":"2003","journal-title":"J Virol"},{"key":"10.1016\/j.transci.2014.10.003_bib0100","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1006\/viro.2001.1279","article-title":"Evidence against an important role for infectivity-enhancing antibodies in Ebola virus infections","volume":"293","author":"Geisbert","year":"2002","journal-title":"Virology"},{"key":"10.1016\/j.transci.2014.10.003_bib0105","doi-asserted-by":"crossref","first-page":"741","DOI":"10.2105\/AJPH.8.10.741","article-title":"The use of convalescent human serum in influenza pneumonia-a preliminary report","volume":"8","author":"McGuire","year":"1918","journal-title":"Am J Public Health"},{"key":"10.1016\/j.transci.2014.10.003_bib0110","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1111\/j.1423-0410.2012.01599.x","article-title":"Strategies for screening blood donors to source convalescent H1N1v plasma for intervention therapy","volume":"103","author":"Parry","year":"2012","journal-title":"Vox Sang"},{"key":"10.1016\/j.transci.2014.10.003_bib0115","first-page":"508","article-title":"Convalescent blood for herpes zoster","volume":"33","author":"Gundersen","year":"1935","journal-title":"Trans Am Ophthalmol Soc"},{"key":"10.1016\/j.transci.2014.10.003_bib0120","first-page":"1007","article-title":"The 1934 Epidemic of poliomyelitis in Denmark. Preliminary report on the epidemiology, clinical features and convalescent serum therapy: (section of pathology)","volume":"28","author":"Jensen","year":"1935","journal-title":"Proc R Soc Med"},{"key":"10.1016\/j.transci.2014.10.003_bib0125","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1136\/jramc-86-06-04","article-title":"Treatment of typhoid fever with convalescent whole blood","volume":"86","author":"Dewar","year":"1946","journal-title":"J R Army Med Corps"},{"key":"10.1016\/j.transci.2014.10.003_bib0130","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1136\/bmj.1.3652.12","article-title":"Convalescent serum in prophylaxis of measles","volume":"1","author":"Nabarro","year":"1931","journal-title":"Br Med J"},{"key":"10.1016\/j.transci.2014.10.003_bib0135","first-page":"673","article-title":"The prevention of chickenpox in high risk children. Comparison of the effectiveness of specific immunoglobulins and of defibrinated convalescent plasma. 414 cases (author's transl)","volume":"8","author":"Avenard","year":"1979","journal-title":"Nouv Presse Med"},{"key":"10.1016\/j.transci.2014.10.003_bib0140","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.1111\/j.1537-2995.2010.02651.x","article-title":"Practical limitations of convalescent plasma collection: a case scenario in pandemic preparation for influenza A (H1N1) infection","volume":"50","author":"Wong","year":"2010","journal-title":"Transfusion"},{"key":"10.1016\/j.transci.2014.10.003_bib0145","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1016\/S0140-6736(79)92335-3","article-title":"Efficacy of immune plasma in treatment of Argentine haemorrhagic fever and association between treatment and a late neurological syndrome","volume":"2","author":"Maiztegui","year":"1979","journal-title":"Lancet"},{"key":"10.1016\/j.transci.2014.10.003_bib0150","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1007\/s10096-004-1271-9","article-title":"Use of convalescent plasma therapy in SARS patients in Hong Kong","volume":"24","author":"Cheng","year":"2005","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.transci.2014.10.003_bib0155","article-title":"The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review and exploratory meta-analysis","author":"Mair-Jenkins","year":"2014","journal-title":"J Infect Dis"},{"key":"10.1016\/j.transci.2014.10.003_bib0160","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1111\/j.1469-0691.2004.00956.x","article-title":"Retrospective comparison of convalescent plasma with continuing high-dose methylprednisolone treatment in SARS patients","volume":"10","author":"Soo","year":"2004","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.transci.2014.10.003_bib0165","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1093\/jac\/dki346","article-title":"Experience of using convalescent plasma for severe acute respiratory syndrome among healthcare workers in a Taiwan hospital","volume":"56","author":"Yeh","year":"2005","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.transci.2014.10.003_bib0170","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1093\/cid\/ciq106","article-title":"Convalescent plasma treatment reduced mortality in patients with severe pandemic influenza A (H1N1) 2009 virus infection","volume":"52","author":"Hung","year":"2011","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.transci.2014.10.003_bib0175","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1056\/NEJMc070359","article-title":"Treatment with convalescent plasma for influenza A (H5N1) infection","volume":"357","author":"Zhou","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.transci.2014.10.003_bib0180","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/0035-9203(84)90107-X","article-title":"The use of Lassa fever convalescent plasma in Nigeria","volume":"78","author":"Frame","year":"1984","journal-title":"Trans R Soc Trop Med Hyg"},{"issue":"Suppl. 2","key":"10.1016\/j.transci.2014.10.003_bib0185","first-page":"19","article-title":"Methylene blue\/light treatment of virus inactivated human plasma: production and clinical experience","volume":"20","author":"Mohr","year":"1993","journal-title":"Infusionsther Transfusionsmed"},{"key":"10.1016\/j.transci.2014.10.003_bib0190","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1111\/j.1537-2995.2006.00867.x","article-title":"Photochemical treatment of plasma with amotosalen and long-wavelength ultraviolet light inactivates pathogens while retaining coagulation function","volume":"46","author":"Singh","year":"2006","journal-title":"Transfusion"},{"key":"10.1016\/j.transci.2014.10.003_bib0195","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1111\/j.1423-0410.2009.01238.x","article-title":"Characterization of plasma protein activity in riboflavin and UV light-treated fresh frozen plasma during 2 years of storage at \u221230 degrees C","volume":"98","author":"Bihm","year":"2010","journal-title":"Vox Sang"},{"key":"10.1016\/j.transci.2014.10.003_bib0200","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1111\/j.1365-2796.2005.01451.x","article-title":"Pathogen inactivation technology: cleansing the blood supply","volume":"257","author":"Klein","year":"2005","journal-title":"J Intern Med"},{"key":"10.1016\/j.transci.2014.10.003_bib0205","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1111\/j.1423-0410.2010.01374.x","article-title":"A comparison of methods of pathogen inactivation of FFP","volume":"100","author":"Rock","year":"2011","journal-title":"Vox Sang"},{"key":"10.1016\/j.transci.2014.10.003_bib0210","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.transci.2006.02.004","article-title":"Update on pathogen reduction technology for therapeutic plasma: an overview","volume":"35","author":"Solheim","year":"2006","journal-title":"Transfus Apher Sci"},{"key":"10.1016\/j.transci.2014.10.003_bib0215","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1111\/j.1365-3148.2009.00963.x","article-title":"Solvent-detergent filtered (S\/D-F) fresh frozen plasma and cryoprecipitate minipools prepared in a newly designed integral disposable processing bag system","volume":"20","author":"El-Ekiaby","year":"2010","journal-title":"Transfus Med"},{"key":"10.1016\/j.transci.2014.10.003_bib0220","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1046\/j.1365-2516.2000.00435.x","article-title":"Virucidal heat-treatment of single plasma units: a potential approach for developing countries","volume":"6","author":"Goubran","year":"2000","journal-title":"Haemophilia"},{"key":"10.1016\/j.transci.2014.10.003_bib0225","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1093\/qjmed\/94.11.599","article-title":"Passive transfer of scrub typhus plasma to patients with AIDS: a descriptive clinical study","volume":"94","author":"Watt","year":"2001","journal-title":"QJM"},{"key":"10.1016\/j.transci.2014.10.003_bib0230","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/S0140-6736(00)02557-5","article-title":"HIV-1 suppression during acute scrub-typhus infection","volume":"356","author":"Watt","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.transci.2014.10.003_bib0235","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1093\/infdis\/165.2.364","article-title":"Passive immunotherapy in AIDS: a randomized trial of serial human immunodeficiency virus-positive transfusions of plasma rich in p24 antibodies versus transfusions of seronegative plasma","volume":"165","author":"Vittecoq","year":"1992","journal-title":"J Infect Dis"},{"key":"10.1016\/j.transci.2014.10.003_bib0240","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1073\/pnas.92.4.1195","article-title":"Passive immunotherapy in AIDS: a double-blind randomized study based on transfusions of plasma rich in anti-human immunodeficiency virus 1 antibodies vs. transfusions of seronegative plasma","volume":"92","author":"Vittecoq","year":"1995","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.transci.2014.10.003_bib0245","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1046\/j.1423-0410.2003.00265.x","article-title":"Nanofiltration of single plasma donations: feasibility study","volume":"84","author":"Burnouf","year":"2003","journal-title":"Vox Sang"},{"issue":"1","key":"10.1016\/j.transci.2014.10.003_bib0250","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1111\/j.1751-2824.2009.01218.x","article-title":"New methods of plasma fractionation \u2013 a presentation of the \u2018mini-pool\u2019 fractionation procedure developed in Egypt","volume":"4","author":"El-Ekiaby","year":"2009","journal-title":"ISBT Science Series"},{"key":"10.1016\/j.transci.2014.10.003_bib0255","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1006\/biol.2002.0332","article-title":"Inactivation of lipid enveloped viruses by octanoic acid treatment of immunoglobulin solution","volume":"30","author":"Dichtelmuller","year":"2002","journal-title":"Biologicals"},{"key":"10.1016\/j.transci.2014.10.003_bib0260","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1006\/biol.2002.0334","article-title":"Enveloped virus inactivation by caprylate: a robust alternative to solvent-detergent treatment in plasma derived intermediates","volume":"30","author":"Korneyeva","year":"2002","journal-title":"Biologicals"},{"key":"10.1016\/j.transci.2014.10.003_bib0265","first-page":"1","article-title":"Clinical evaluation of minipool immunoglobulin plasma fraction in primary immunodeficiency patients. 5A-S42-02","volume":"107","author":"El-Ekiaby","year":"2014","journal-title":"Vox Sang"},{"key":"10.1016\/j.transci.2014.10.003_bib0270","series-title":"Rossi's Principles of Transfusion Medicine","article-title":"Pathogen Inactivation","author":"Solheim","year":"2009"},{"key":"10.1016\/j.transci.2014.10.003_bib0275","series-title":"Potential for use of convalescent plasma in management of Ebola. 14 August 2014","author":"BRN WBRN","year":"2014"},{"key":"10.1016\/j.transci.2014.10.003_bib0280","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.tmrv.2006.11.001","article-title":"Modern plasma fractionation","volume":"21","author":"Burnouf","year":"2007","journal-title":"Transfus Med Rev"},{"key":"10.1016\/j.transci.2014.10.003_bib0285","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1111\/j.1423-0410.2009.01226.x","article-title":"Intravenous immunoglobulin G: trends in production methods, quality control and quality assurance","volume":"98","author":"Radosevich","year":"2010","journal-title":"Vox Sang"},{"key":"10.1016\/j.transci.2014.10.003_bib0290","first-page":"189","article-title":"Annex 4. Recommendations for the collection, quality control and regulation of human plasma for fractionation","volume":"941","author":"WHO","year":"2007","journal-title":"WHO Tech Rep Ser"},{"key":"10.1016\/j.transci.2014.10.003_bib0295","doi-asserted-by":"crossref","first-page":"297","DOI":"10.4269\/ajtmh.1991.45.297","article-title":"Parasitological and clinical human response to immunoglobulin administration in falciparum-malaria","volume":"45","author":"Sabchareon","year":"1991","journal-title":"Am J Trop Med Hyg"},{"key":"10.1016\/j.transci.2014.10.003_bib0300","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1111\/j.1537-2995.2005.00179.x","article-title":"Purification of severe acute respiratory syndrome hyperimmune globulins for intravenous injection from convalescent plasma","volume":"45","author":"Zhang","year":"2005","journal-title":"Transfusion"},{"key":"10.1016\/j.transci.2014.10.003_bib0305","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1086\/519392","article-title":"West Nile virus neutralization by US plasma-derived immunoglobulin products","volume":"196","author":"Planitzer","year":"2007","journal-title":"J Infect Dis"},{"key":"10.1016\/j.transci.2014.10.003_bib0310","doi-asserted-by":"crossref","DOI":"10.2807\/ese.16.10.19812-en","article-title":"Increasing West Nile virus antibody titres in central European plasma donors from 2006 to 2010","volume":"16","author":"Rabel","year":"2011","journal-title":"Euro Surveill"},{"key":"10.1016\/j.transci.2014.10.003_bib0315","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.jaci.2009.09.008","article-title":"Hepatitis A virus antibodies in immunoglobulin preparations","volume":"125","author":"Farcet","year":"2010","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.transci.2014.10.003_bib0320","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1086\/506363","article-title":"Measles-virus\u2013neutralizing antibodies in intravenous immunoglobulins","volume":"194","author":"Audet","year":"2006","journal-title":"J Infect Dis"},{"key":"10.1016\/j.transci.2014.10.003_bib0325","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1016\/S0140-6736(14)61693-7","article-title":"Ebola: a call for blood transfusion strategy in sub-Saharan Africa","volume":"384","author":"Burnouf","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.transci.2014.10.003_bib9020","series-title":"Use of convalescent whole blood or plasma collected from patients recovered from Ebola Virus Disease for transfusion, as an empirical treatment during outbreaks","author":"WHO","year":"2014"}],"container-title":["Transfusion and Apheresis Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1473050214001724?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1473050214001724?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T08:49:30Z","timestamp":1761468570000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1473050214001724"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,10]]},"references-count":65,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2014,10]]}},"alternative-id":["S1473050214001724"],"URL":"https:\/\/doi.org\/10.1016\/j.transci.2014.10.003","relation":{},"ISSN":["1473-0502"],"issn-type":[{"value":"1473-0502","type":"print"}],"subject":[],"published":{"date-parts":[[2014,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ebola virus convalescent blood products: Where we are now and where we may need to go","name":"articletitle","label":"Article Title"},{"value":"Transfusion and Apheresis Science","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.transci.2014.10.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}